Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons Marijuana Stocks May Go Up in Smoke

By George Budwell – Updated Apr 18, 2019 at 4:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pot shares might be wildly overvalued right now. Here's why.

Valuations across the nascent legal marijuana space have been exploding over the last five years. The core reason is that the steady march toward legalization across the globe is widely expected to result in marijuana becoming one of the most valuable industries in the entire world within a decade's time.

Keeping with this theme, Canopy Growth (CGC -3.52%) co-CEO Bruce Linton has suggested that legal cannabis could eventually morph into a $500 billion industry. His estimate implies that sales of marijuana and marijuana-derived products will rise at a staggering compound annual growth of rate of around 35% for the next 10 years.

Marijuana buds sitting next to a stack of $100 bills.

Image Source: Getty Images.

But there are three common-sense reasons to think that the cannabis market might fall well short of these lofty projections.   

1. Dried flower prices could crash

Quebec-based HEXO (HEXO 0.18%) is among the few cannabis-oriented companies that has been truly up front about the state of the rapidly evolving marijuana space. Specifically, the company has openly admitted that up to 80% of the entire industry will likely be controlled by only a handful of entities within a few years. 

There are two overarching issues that are likely to drive a widespread consolidation phase across the industry soon. First, the Canadian legal marijuana market should experience a supply glut in no more than two years. And if other major Western markets fail to open up in a timely manner to absorb this overproduction, dried flower prices will undoubtedly crash in Canada. In turn, smaller companies like HEXO will either have to merge with their peers to remain solvent, or move deeper into less-competitive niches to make a living (more on this later). 

Second, the legalization of marijuana at the federal level in the United States may not be the boon to the industry that many are predicting right now. Growing marijuana at home is relatively easy and often more cost-effective than going to a legal retailer. Many Americans may also choose to grow at home in order to keep their cannabis habit out of the public purview. 

The key point is that dried flower prices may have already reached their high-water mark in Canada and in states that permit the sale of cannabis. Therefore, many of these Canadian cannabis companies could struggle to turn a profit on a consistent basis -- even if America does green-light recreational use nationwide.       

2. Edibles are set to disappoint

There's a very good reason that the first major deals in this space revolved around cannabis-infused drinks. HEXO, for instance, paired up with Molson-Coors to develop a line of nonalcoholic cannabis drinks through a joint venture called Truss, and Canopy Growth signed a major partnering deal with Constellation Brands to do the same last year.

The underlying reason is that the cannabis-infused beverage market is probably going to be one of the few areas where companies can actually establish a competitive moat. Consumers can't easily replicate these products, even if they have access to boatloads of cheap, homegrown weed. 

But cannabis-infused candies, confections, and even full-on meals present no such barrier for the most part. As a result, a healthy proportion of cannabis enthusiasts may end up simply making their own edibles -- instead of paying a premium at retail outlets -- once federal prohibition ends in the United States. If so, billions of dollars in projected annual sales would fail to materialize from this key market segment.   

3. Intellectual property may not matter

Medical marijuana is widely expected to be a crucial value driver for the industry. This notion, though, is arguably based on an extremely shaky premise.

Top players in the field are gearing up for trials of a range of medical marijuana products in the coming years. By doing so, these companies hope to build a competitive moat through intellectual property rights. 

Unfortunately, cannabis companies may not be able to borrow from big pharma's playbook so easily. Patients will likely have easy access to cannabis strains that closely mimic the Food and Drug Administration-approved versions and that cost significantly less. There are already thousands of cannabis varieties covering a wide spectrum of tetrahydrocannabinol to cannabidiol ratios. A patent isn't going to solve this fundamental problem.  

The one potential exception is the rare cannabinoid product series being developed by Cronos Group (CRON -1.05%) and Ginkgo Bioworks. If successful, Cronos and Ginkgo would have a unique product portfolio that can't be easily replicated or imitated. But there's no guarantee that Cronos' rare cannabinoid venture will prove fruitful -- underscoring the high degree of uncertainty surrounding this fledgling space in general. 

Check out the latest Cronos and Canopy Growth earnings call transcript.

Conclusions

Pot stocks have been soaring based on the assumption that the industry will grow at record-breaking levels over the next decade. But there are fairly solid reasons to think that these growth estimates may be overly optimistic. 

The biggest problem is that the main product categories -- outside of the cannabis-infused beverage segment -- all have exceedingly weak competitive moats due to marijuana's underlying biology. And at some point, this fundamental problem will start to show up in quarterly earnings reports across the industry, perhaps marking the end of the market's love affair with all things marijuana.

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing. The Motley Fool recommends Constellation Brands and HEXO. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.74 (-3.52%) $0.10
Cronos Group Stock Quote
Cronos Group
CRON
$2.83 (-1.05%) $0.03
Molson Coors Beverage Company Stock Quote
Molson Coors Beverage Company
TAP
$47.49 (-0.40%) $0.19
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
STZ
$232.66 (0.60%) $1.40
HEXO Stock Quote
HEXO
HEXO
$0.17 (0.18%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.